Joanna Holtzman
Director of Investor Relations and Corporate Communications
Replay available
Compugen (NASDAQ:CGEN) Q2 2020 earnings call, held 2020-07-30. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/compugen-ltd-cgen-q2-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:01 Ladies and gentlemen, thank you for standing by. Welcome to Compugen's second quarter 2020 results conference call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available in the investor section of Compugen's website, www.cgen.com. As a reminder, today's call is being recorded. I would now like to introduce Joanna Holtzman. Compugen's Director of Investor Relations and Corporate Communications. Please go ahead.
0:35 Thank you, Operator, and thank you all for joining us today. With me from Compugen are Dr. Anat Cohen-Dayag, President and CEO, Dr. Henry Attaway, Chief Medical Officer, Ali Krashen, CFO and COO, and Dr. Eran Ophir, VP Research and Drug Discovery. Before we begin, I would like to read the following regarding forward-looking statements. During the course of this conference call, the company may make projections or other forward-looking statements regarding future events or future business outlook, our development efforts and their outcome, our discovery platform, anticipated progress and timelines for our programs, financial and accounting related matters, as well as statements regarding our cash position.
1:24 We wish to caution you that such statements reflect only the company's current expectations and that actual events or results may differ materially. You are kindly referred to the risk factors in cautionary language contained in the documents the company filed with the Securities and Exchange Commission, including the company's most recent annual report on Form 20F filed on February 24, 2020. The company undertakes no obligation to update projections or forward-looking statements in the future. I will now turn the call over to Anat.
1:58 Thank you, Ilana. Good morning and good afternoon, everyone, and welcome to our second quarter 2020 corporate and financial update. As Ilana mentioned, with me today are Dr. Henry Adewoy, our Chief Medical Officer, Ari Krushing, our CFO and COO, and Dr. Eran Ophir, our VP Research and Drug Discovery. After my prepared comments, Henry will review the progress across our clinical programs and Ari will review our financial statements and position. We will all be available for the Q&A session. We have reached an exciting new phase of development at Compugen.
2:44 Today, there are three clinical programs, COM701, COM902, and Bay 190-5254 addressing drug targets we discovered computationally. COM701 and COM902, developed internally, are designed to strategically evaluate the genome axis as a potentially transformative checkpoint axis for cancer immunotherapy treatment. Henry will provide detailed updates across these programs later in the call, but first, I want to share what we believe are important developments for COMPIGEN and the broader immunoncology space that leave us increasingly optimistic about our drug candidates and distinctive clinical development path.
3:35 As a reminder, COMPIGEN's internal computational discovery platform has enabled the discovery of two important new checkpoints in the DINAM axis, PDR-AG discovered by COMPIGEN and TIGIT, discovered by CompleGen and at the same time also by others. Our lead program, COM701, targets PVRIG, while COM902, now also in the clinic, targets TIGIT. It is important to note that we identified that PVRIG and TIGIT are part of a parallel and complementary inhibitory pathway in the denim axis. and we have preclinical data demonstrating that blocking PVRIG together with PIDGIT may be required in certain tumor types in order to generate or enhance an anti-tumor immune response.
4:31 In addition, our preclinical work, supported also by others, provides the foundation of our hypothesis that there is an intersection between the two pathways on the denim axis , and the PD-1 pathway. Specifically, our findings suggest that the simultaneous blockade of these three pathways has the potential to synergistically enhance anti-tumor immune responses in certain patients' populations where the genome axis plays a role and who therefore are probably not responsive to PD-1 inhibitors alone. As such, the blockade of these two denim axis pathways have the potential to expand immune oncology treatment options to cancer patients who are not responsive to currently available drugs.
5:30 It is quite remarkable to think that just a few quarters ago, of these three targets, only PD-1 was clinically validated. We have come a long way in a very short time, and are thrilled to now have initial signs of clinical activity by PVRIG and TGIT validated in the clinic by others. Taken together, these data increase our confidence in our hypothesis that in certain patient populations where these three pathways are dominant, blocking the denim axis and specifically the addition of PVRIG blockade to TIGIT and PD-1 blockers may be a critical component in driving cancer immunotherapy treatment responses.
6:22 I want to dive in a bit more into PVRIG and TIGIT. It is important to recognize that while these are important complementary checkpoints in the same genome axis, they are in fact distinct. First, PVRIG and TIGIT bind preferentially to different ligands. PVRL2 and PVR respectively. In addition, and highly relevant to our clinical programs, PVRL2 and PVR are differentially expressed on different tumor types. Importantly, PVRL2 expression is more dominant compared to PVR in certain cancers such as breast, endometrial, and ovarian.
7:08 This is significant because in these PVRL2 dominant indications, we expect that PVRLG must be blocked in order to drive antitumor immune responses. Furthermore, PVRL2 is more expressed on various myeloid populations, mainly DC subsets. These immune cell types have been shown recently to be important in the PD-1 pathway. In addition, PVRLG antigens are not necessarily expressed on same immune cell types. While both expressed on T cells and NK cells, TGIT is highly expressed on Tregs relative to PVRIG. These findings, with the totality of our functional data, suggest that PVRIG blockade should support synergistic effects with PD-1 and or TGIT inhibitors and that these pathways are not redundant.
8:08 Therefore, as the only company with wholly owned clinical assets targeting both PBRG and TGIT, we believe we're uniquely positioned to evaluate the blockade of the denim axis within without PD-1 blockade and assess its potential to drive robust immune responses in patients. In line with our preclinical work, our initial clinical data suggests Thank you very much. as well as in dual and triple combination regimens that we believe will allow us to comprehensively extract the value of our drug candidates addressing these new checkpoints.
9:18 So starting first with our COM701 clinical studies. In April, we presented at AACR the dose escalation data from both the COM701 monotherapy and combination arm with Bristol-Merrick squids of Devo. These data included all eight monotherapy dose escalation cohorts and four of a total of five cohorts from the dual combination arm. We were thrilled to observe two partial responses, one from each arm, with both having presented very encouraging durable responses of more than six months as of the data cutoff date. We were also highly encouraged with both safety and tolerability and disease control rates in both arms.
10:11 We believe the notable durability of responses observed with COM701 is particularly significant given that these results were achieved in a dose escalation setting and in heavily pre-treated patients. These data serve as an important initial clinical validation of PVRIG as a new immune checkpoint with a role in cancer immunotherapy. And we're excited to continue advancing this program for the many patients who currently do not respond to available treatments, potentially because the dominant inhibitory checkpoints in their tumors were not being targeted. So what is next for COM701?
10:58 This quarter, we initiated enrollment for the monotherapy expansion cohort, which is designed to evaluate the safety and tolerability of COM701 as a recommended dose for expansion. This study utilizes a biomarker-informed strategy to focus on tumor types where we believe the PGRHG pathway may play a role based on our preclinical genome access expression data and those escalation clinical results. We were excited to start this study which was also met with strong interest from our principal investigators and we're excited to share that the enrollment is progressing as planned.
11:43 We remain on track to complete enrollment in 2020 and report initial data from this trial as previously indicated in the first half of 2021. We recently completed enrollment in fifth and last cohort of the combination dose escalation study of COM7-1 with Optivo and intend to provide the additional cohort data most likely at the same time as the initial monotherapy expansion cohort data in the first half of 2021. Finally, moving to our triple combination study. We remain on track to begin the Phase 1-2 study to evaluate COM701 in combination with Obdivon and Bristol-Mers Squibb's anti-tigit antibody in the second half of this year, following the recent clearance of the IND by the FDA. We're working closely with Bristol-Mers Squibb on this study and are very pleased with their continued support and involvement in our collaboration.
12:50 This program allows us to directly test our hypothesis of an intersection between the PDRG, TGIT, and PD-1 pathways, and that the simultaneous blockade of these three pathways has the potential to synergistically enhance anti-tumor immune responses in selected patient populations not responsive or refractory to PD-1 blockers alone. As I have reviewed today, We believe there is now significant data, both clinical and preclinical, that support this strategy and we look forward to leveraging our position with our wholly owned clinical candidates against both PGRG and TIGIT.
13:37 We're highly enthusiastic about this targeted, science-driven, clinical development program of COM701, which we believe has the potential to broaden the therapeutic benefit of checkpoint inhibitors to tumor types where they have previously not been successful. Moving next to COMP902, our anti-TGT therapeutic antibody. As I mentioned earlier in the call, new data presented by others over the past few months provided important clinical validation of TGT as an immunotherapy checkpoint. We're thrilled to see this data, which we believe further supports our triple pathway hypothesis, and we're excited to initiate this quarter the dose escalation study of COM902.
14:31 We anticipate disclosing initial data from this study next year. I would like to reiterate that while PDIS is now a clinically validated target being evaluated by us and others in biopharma, Compugen is the only company with clinical assets targeting both PDRG and TGIT in its portfolio, allowing us to fully exploit the potential of blocking these parallel and complementary members of the genome axis to drive robust immune responses. Before I turn the call over to Henry, I would like to briefly touch upon the continued challenges associated with COVID-19. We're fortunate in that we're not experiencing significant impact on our activities for 2020.
15:22 In fact, as indicated in our last call in May, we anticipate meeting our upcoming milestones and data readouts, including completing enrollment in the COM-701 monotherapy expansion cohort this year, and disclosing initial data from the study in the first half of 2021, Together with the data from the additional cohort of the dose escalation of COM701 in combination with Obdivo, as well as disclosing initial data from the COM902 dose escalation study in 2021. COVID-19 has introduced challenges in our work, and I am enormously proud of our team having watched them rise to overcome the extraordinary circumstances we are facing.
16:14 Their dedication allows us to continue to advance our programs with the ultimate hope of broadly expanding the reach of cancer immunotherapy. We're grateful to our partners, investigators, and shareholders and look forward to continued progress. With that, I will turn the call over to Henry to review our clinical programs.
16:39 Thank you, Anat, and good day to everyone. As Anat already mentioned, In April, we presented at the first AACI virtual meeting the dose escalation data from both the COM701 monotherapy and combination arm with Bristol-Myers Squibb's Nivolumab. This data included all monotherapy dose escalation cohorts, which is now completed with four of five cohorts from the dual combination arm. We were highly encouraged with both safety and tolerability and initial anti-tumor activity with this data that showed disease control rates of 69% or 11 of 16 patients in the immunotherapy arm and 75% or 9 out of 12 patients for the combination arm.
17:28 We, as well as the principal investigators, were also encouraged to observe two partial responses. One partial response was from the immunotherapy arm in a patient with microsatellite stable platinum resistant primary peritoneal cancer, a type of ovarian cancer. And the second partial response was from the combination arm in a patient with microsatellite stable colorectal cancer. Both patients presented very encouraging durable responses of more than six months. I'd also like to remind you that both indications Ovarian and colorectal cancer are included in our COM701 monotherapy expansion cohort and we are eager to evaluate COM701 at the recommended dose for expansion in these tumor types that are generally unresponsive to immune checkpoint inhibition.
18:22 I would also like to highlight the durability of responses observed in our ongoing study with COM701. Across all cohorts, We reported durable responses of acute stable disease or partial response for over 6 months in 6 out of 28 patients, or 21% of patients, and in 2 of 6 patients, 33%, in microsatellite stable colorectal cancer. At the time of the presentation, 50% of patients, or 6 out of 12, in the combination arm remained unstudied with a number of patients on treatment for over 200 days. Taking together, the preliminary anti-tumor activity and durability of responses potentially serve as proof of concept that inhibition of PDI by COM701 is likely to translate into therapeutic benefits for patients.
19:19 Looking at the next steps in this program, we have completed enrollment in a dose escalation combination arm of COM701 with nivolumab, and we continue to accrue clinical and laboratory data in these patients. In May, we announced that the first patients were those in the COM701 monotherapy cohort expansion. We plan to enroll a total of 20 patients with advanced solid tumors, including advanced non-small cell lung, ovarian, breast, endometrial and colorectal cancer who have exhausted all available standard therapies. The key objective is to evaluate the safety and tolerability of COM701 at the recommended dose for expansion.
20:06 Additional exploratory objective is the preliminary evaluation of the anti-tumor activity of COM701 monotherapy at the recommended dose for expansion. A third objective is to conduct retrospective biomarker analysis examining DNAM access expression in biopsies obtained from patients before and during study treatment to inform on the DNAM access and possibly to guide patient selection for other trials. We remain on track to complete enrollment in 2020 and report initial data from this trial in the first half of 2021. Our triple combination study is also advancing to the clinic.
20:53 We recently announced IMD clearance from the FDA for our Plant Phase 1-2 open-level study, which will evaluate the safety, tolerability, and anti-tumor activity of COM701 in combination with nivolumab and Bristol-Myers Squibb's anti-tumor antibody. The study will evaluate selected tumor types, namely ovarian cancer, Endometrial Cancer, as well as a biomarker-driven arm of tumor types with high expression of PDRL2. The study will dose-escalate COM701 with six doses of nivolumab and DMS-986207. We remain on track to begin the study in the second half of this year.
21:38 Despite the challenges of COVID-19, we also initiated our Phase I dose-escalation trial of COM902. Enrollment of patients in this study is on track. As of today, we have not observed significant impact on enrollment of patients in our ongoing COM701 study. Having said that, we continue to remain in close contact with the principal investigators and sites to proactively monitor the situation. For us and the principal investigators, the safety of patients on the study remains our number one priority. Before turning the call over to Ari, I would like to second Anat's appreciation of the Compligene team for their strong execution in advancing our clinical studies, as well as to thank our investigators for their continued support and commitment to our studies, and of course, our patients and their families.
22:36 Ari. Thank you, Henry. Good morning and good afternoon to everyone. Our financial results for the second quarter of 2020 released this morning continue to reflect a solid financial position with an improved cash balance and linear expense structure, which gives us the flexibility and ability to move fast and evaluate the potential of our clinical programs in the various indications and combination. R&D expenses for the second quarter of 2020 were $4.4 million compared with $4.9 million for the same period in 2019.
23:21 R&D expenses reflect costs associated with extended clinical programs which now include the COM701 monotherapy expansion cohorts, COM701 in combination with Obdivo dose escalation, and dose escalation study for COM902. Net loss for the second quarter of 2020 was $6.2 million or $0.08 per basic and diluted share compared with a net loss of $6 million or $0.10 per basic and diluted share for the same period of 2019. As of June 30, 2020, we had approximately $136 million in cash and cash-related accounts compared with approximately $121 million as of March 31, 2020.
24:14 The increase in our cash balances of approximately $15 million during the second quarter is attributed to approximately $21 million of net proceeds received from exercise of warrants, exercise of employee options, and the partial exercise of underwriters option in connection with our recent public offering offset by our operating expenses and working capital needs. Going into the second half of 2020, our ongoing R&D expenses are expected to increase slightly as planned compared to the first half of 2020 to support the initiation of our Phase I-II triple combination study.
24:59 Our cash balance at the end of the year is expected to be above $120 million. Thank you for joining us today, and on behalf of the entire CompuGene family, we hope you stay safe and healthy. Thank you, and with that, we will now open the call for questions. Thank you. Ladies and gentlemen, at this time, we will begin the question and answer session. If you have a question, please press star 1. If you wish to decline from the polling process, please press star 2. If you are using speaker equipment, Kindly lift the handset before pressing the numbers. Please stand by while we poll for your questions.
25:52 The first question is from Stephen Willey from Stiefel. Please go ahead.
26:02 Yeah, good morning, everyone. Thanks for taking the questions and congratulations on the progress. Maybe just a couple of questions regarding the triple trial that's going to initiate later this year. So I know the tumor type selection strategy here is going to be predicated on a PVRL2 biomarker. Can you speak to what you know about the correlation of PVRL2 high Thank you for joining us. mostly being PD-L1 low.
27:05 So, hi Steve. So, in general, the data that we have and we shared is that there are tumor types that have PDRL2 high that are also PD-L1 low. And these are mostly the tumors that we selected to focus our studies on the monotherapy and the triplets as well. But also PVRL2 high is also found on tumor types where there is a PD-L1 high. So it's not that it is only characterizing the PD-L1 low, but definitely when we look at the unmet need and where we think that the PVRID pathway has a role and that's the first that we want to test is that mostly on indications that are the breast, ovarian, endometrial, colorectal, but we also mentioned non-small cell and cancer, and obviously there are additional indications where there is a PVL1 high and PVRL2 high.
28:16 Okay. And then can you speak to what the starting dose of COM701 is going to be on a fixed dose? and the background of TIGIT PD-1. I guess when you think about biomarker strategy for the triple, what are the one or two biomarkers that you think would be the most important in terms of providing a surrogate of on-target PBRG activity? Thanks.
28:50 So I'll start with the biomarker question, and then I'll let Henry answer those that come to the one question. So on the biomarker front, obviously, we have our hypothesis that is based on preclinical data and also analysis of human tumor samples that we were conducting. But at the end of the day, we're still at the exploratory stage. We are going to test not only PDRL2, by the way. We're looking to look at different dinamases members. We're also going to look at different and other biomarkers. We want to understand how the tumor microenvironment looks like pre-treatment and on treatment. So we're going to collect all this information and look at it. At the end of the day, the study that we're conducting, the three-step study that we're conducting, we do aim to look at PGRL2 high patient populations, but until we get to this point, which we still need to go through the study and go through the dose escalation, we will collect biomarker information and be more educated about the hypothesis that we have.
30:12 All right.
30:13 Thank you very much. Go ahead, sir.
30:17 Oh, no. I was just going to ask you about starting this.
30:20 Yes. So the starting dose, we haven't disclosed. But safe to say that the dose we will select will be informed by the dose that we've observed on the monocerati study and also the dual-combination and those escalation parts of the COM701 study also. And the other things that we're going to use to determine the starting dose are things that correlates with the PD and the PK of COM701. As the study starts to enroll and starts to generate data, we'll be able to disclose the doses that we've used both the starting dose and the dose escalation doses subsequently. But as a reminder, The doses of PMS-986207, which is antibody, and the dose of nivolumab are fixed. So they're both 480 milligrams each, and the dose that will be escalating will be the dose of COM701.
31:27 Understood. Thanks for taking the question. The next question is from Diana Graybotch of SDB Leerink. Please go ahead.
31:49 Hi, this is Dana. Thank you so much for the question. Two for me. The first sort of staying on the triplet and the plan for understanding the signal. You know, with the triplet and single arm data, one worry I have is how we're going to untangle the contribution. from PVRIG, TIGIT, and PD-1. I wonder if you can speak to what would be a really great signal. Do you think we can start to get an efficacy signal for the triplet in this sort of dose escalation and cohort expansion? Or can you speak to when you might plan to move into randomized trials to get a stronger signal?
32:31 So, hi Dana. I'll start and I'll let Henry add. I'll just say that obviously it's a phase one to study, but we didn't share the design yet. And this is obviously, it's hard to answer your question without really being able to answer about to share the design. But this, you know, we will share the design after we start the study. Also, I'll say that while your question is completely relevant, I'll just mention that we're addressing tumor types that are not responsive to PD-1 blockers and it may make it a little bit easier to compare to historical data of these drugs and assess the contribution of COM-71. But definitely, you are correct.
33:33 In our studies, we're still at the stage of signal-seeking, but in the triplet, obviously, we will need to relate to randomization at a certain point. So this is what I'll say. Henry, would you like to add anything on this?
33:49 Yeah, I'd just like to add that it's a very good question, Dana. One of the things that is going to be helpful for us in determining the contribution of COM701 in the triplet study is the data that we've already accrued from the immunotherapy study, dose escalation, and the patients that were also enrolling on the expansion cohort with COM701 immunotherapy. In addition, the patients that we have on the dose escalation with COM701 Nivolumab will also inform on what the relative contribution of COM701 is when added to Nivolumab. What to note specifically is that we're fortunate in the sense that, so for example, for the monotherapy dose expansion cohort that is currently enrolling, that we have patients that are very similar to the patients that will enroll in the and Triplet Dose Expansion Cohort. So that will inform in a way what the probable relative contribution of COM701 is. But at the end, in summary, I think the randomized study is what will actually be able to provide definitive proof of what the contribution of COM701 is.
35:16 The other thing to add, Dana, is you asked about what the responses and anti-tumor activity that will help us delineate the contribution, infer the contribution of COM701. What Anak has already mentioned in her prepared comments is that the patient population that we are actually enrolling on this study, patients with ovarian cancer, patients with endometrial cancer, patients with high expression figure IELTS, These are patients who have exhausted all available therapies and therefore it really will not be too difficult to see when you compare to historical control what the contribution of COM701 with the other two components are if that's higher in the triplet compared to either what the patient came in with in terms of responses before they became enrolled on the study or historical data, like data from patients who have been exposed to immune checkpoints with ovarian cancer or endometrial cancer, which is typically low-digit numbers, maybe about 9%, 10%, and if one is generous, maybe up to about 2% or 15%.
36:33 If those numbers are higher in the triplet, then you know we have a signal. So those are the ways we're looking at it.
36:40 Maybe one follow-up on that. So it all makes a lot of sense, but I guess the challenge is we don't have any data with Pidget and PVRIG on its own that sort of keys out the relative contributions of those two novel and parallel pathways. And I wonder if you could speak to that.
37:04 Go ahead, Henry. Go ahead.
37:07 Yeah, so it's correct that we don't have data, conclusive data, that is. Of course, there are data in small subsets of patients who've been enrolled in other studies, but not the study that we're currently conducting. But, Dana, what's important is that if we're looking at the patient population and the genome axis as a whole, and we're observing that The responses or the antitumor activity that we're observing in that study, the triplet study, is higher compared to what the historical data is. That still leaves open the plan to have randomization, where not only are we trying to figure out what the contribution of COM701 is, but the randomization will be done in such a way that we're also inferring And one more piece of information for this, and this, you know, it's not a direct comparison, but it would allow us to also
38:31 is the study that we're planning to conduct with our TB inhibitor and COM701 as a doublet. And that will also allow us to better understand the relative contribution as compared to PD-1 itself. So there are different combinations here, and we will need to make sure that we compare it well, apples to apples, and do the right randomizations at the right times.
39:05 Great. And then one more question for me, sort of on the biology, asking you to speculate and hear your hypotheses. I think we now see three different triple or four different triple mechanisms with TIGIT and PD-1. We see, of course, PVRIG. We see adenosine. We saw recently EMD Serono posted a trial combining their TGF-beta trap with their own TIGIT, and then, of course, chemo. and I wonder if you think across all those mechanisms of triplet, why PVRIG stands out to you as the best mechanism to add on top versus the other three?
39:48 It's really based on our analysis as to where these pathways are dominant and it won't be relevant for all the patient populations, but in certain patient populations where these three pathways or two of them are dominant, You need to block and to release this negative co-stimulatory effect. So it doesn't rule out that in other patients you'll get some additional response when you combine with additional mechanisms of action. But we think that in tumor types where two or three of the pathways are there and are signaling negative inhibitory signals, You need to block them. So this is our focus.
40:39 Thank you. That's all for me. Thank you very much. The next question is from Mark Breidenbach of Oppenheimer. Please go ahead.
40:53 Hey, guys. This is Matt. I'm from Mark. Thanks for the update. Anat or Henry, just wondering how you're looking at the Roche-Sigit data and whether or not It's affecting your development plans for 902. Should we expect further emphasis in lung cancers going forward, or do you anticipate kind of letting the data kind of guide you?
41:14 Hi, Matt. I'll let Henry describe the clinical aspect, but I'll just say that from our perspective, Being able to see the TG pathway being clinically validated in a randomized study, yes, one indication, but it's validated in a randomized study, it gives us more comfort because, as I mentioned in our prepared remarks, when we started this path and when we came up with these hypotheses, only the PD-1 pathway was clinically validated. And right now, we have some signs for the TGs, we have Very initial sign for PBRID, so we get more comfortable with our plan forward and with our strategy for combination.
42:10 So it's just strengthening our belief in the hypothesis. Our plan for coming to remain the same, but I'll let Henry. Henry, would you like to relate to the clinical front?
42:23 Yes. Thank you very much, Magda. The thing to say in addition to what Anat has said is that what we are doing statistically for COM902 is independent of what other competitors are doing. We are doing things with the science guiding essentially all the tumor types that we're selecting, the combinations that we're going to be doing, and we've already disclosed in our corporate deck that for COM902, one of the key things is to look at the PD-1 and the PD-L1 free regimen when we're combining COM902 and COM701 in the two more tests that are relevant. So, the combination strategy is independent and it's driven by the science that Anat has mentioned.
43:10 That makes sense. And then maybe another question on 902. Could you speak to any differences in the structure of the antibody Specifically between the Roche and Bristol TIGIT antibodies, are there any features that you think might improve on safety or efficacy? Thanks.
43:31 Yeah, let Eran answer this question.
43:36 Yes, so basically both antibodies are blockers of the TIGIT-PVR interaction. I would say that the main difference that is highly discussed also is the FC and the binding to FC-receptors. Obviously Genentech has the human Ig1 which binds the FC-receptors and BMS-1 has a mutated Ig1 which does not bind the FC-receptors. And there are a lot of debates about this issue whether FC-receptor binding is important or not. And I think this could be looked at from three aspects. is that most of the motivation to use an antibody that binds the FC receptors for digits mostly came from murine studies. And actually the FC receptor system, the murine system is very different from the human. The composition, the identity of cell types, et cetera.
44:26 So to use murine studies to choose FC isotype of antibody is a bit challenging and problematic. The second part, which is highly linked to the first one, is that the history taught us that this is maybe a problematic way. For CTLA-4, for example, in the urine studies, a very strong depletion of Tregs with CTLA-4 and actually ipilimumab does not matter. And also PD-L1 was shown to be more efficient actually to require FC receptor binding for its activity in the mouse. And this is not what we see in the clinic from antibodies that bind or do not bind PD-L1. So this is for the transversal ability from our human epithelial binding. And lastly, when you have a human Ig1 antibody like Genentech, while you have maybe the potential to deplete suppressive cells like Treg, you also have the potential to deplete effector cells like CD8 and AK cells that actually these are the same type of cells you want to enhance their activity.
45:24 So we chose to focus on a pure blocker, Since, again, the expression pattern of TGT is overlapping between Tregs and effector cells. So, basically, we chose to focus on a pure blocker, like the PD-1 blockers, to enhance activity of T-cell and anti-cells without the risk of depleting no Treg and also effector cells.
45:48 Awesome. Congrats on the progress, guys. The next question is from Ashtika Gunwarden of SunTrust. Please go ahead.
46:03 Hi, guys. Ashtika from SunTrust here. Thank you for taking my questions. So the preclinical data has suggested that PVRIG inhibition induces TIGIT and PD-1 expression. So I'm wondering, is there logic to taking a Do you have a sequencing strategy when you're thinking of dosing your triple combination? Then I have a follow-up after that.
46:33 Yeah, well, it's an interesting idea, but I think that this in vitro induction that we see, it will be difficult to translate into dosing sequences in patients. Basically, in terms of biology, yes, the feverology are correlated to other pathways, and this may expand in part the synergism between all these three pathways. but I think that to link this into kinetics of appropriation in patients would be a bit challenging.
46:59 Got it. Okay. And I know COVID had a bit of an overhang in terms of recruitment for all clinical trials, but I'm just wondering, has the presentation at AACR impacted your recruitment rates on your ongoing study?
47:23 Yes, Tika, so we've received a lot of inquiries about enrollment into our clinical study since we, Dr. Ryan Sullivan from our general hospital presented at AACR, like enacted in our prepared comments, fortunately for us at this time, we have not been adversely impacted by the COVID pandemic. In fact, we've seen a lot of interest, not just by the investigators, but an interest from also patient groups also wanting to participate in our clinical trial. And hopefully this continues. So we haven't been absolutely impacted by the COVID. And in fact, we've been helped by the presentation that Dr.
48:09 Ryan Sullivan gave at the ACR.
48:14 Great. Thanks, guys, for taking my questions. That's all from me. The next question is from Colin White of Jefferies. Please go ahead.
48:30 Hello, it's Colin White from Jefferies here. I just had one question. It was about yesterday GSK announced that they've moved their anti-CD96 into clinical development. The first patient has been dosed in a Phase 1 study. So I just wondered if CD96 was obviously that target that you looked at What do you think about that as a target? Like why you maybe pursued PVRIG instead? Or if you think that this might be a competitive threat or it might be something that could be used possibly in combination? Thank you.
49:08 Yes, thank you. So obviously we have years of research of this genome axis. So obviously we're taking a look also on the CD96 and later on and related.
49:18 Yes, so basically CD96 binds PVR like TGIT, and it doesn't bind PVRL2 like PVRLG, so I would say the pathway is related to PVRLG because of course it's part of the DINAM access, but it's not highly related to PVRLG because it doesn't bind the same ligand. In addition, the affinity of CD96 to PVRL is actually one log lower than the affinity of TGIT to PVRL, so then comes the question is how dominant is this target compared to TGIT in terms of binding to PVRL and activity. And finally, the biology of CD96 is a bit more complex. I mean, for example, there are some human-mouse differences. In the human, there is an intercellular part which is different from the mouse, which actually indicates activity or a signal, potential activity or a signal.
50:04 And indeed, in our hands, we actually checked and also published. We didn't see any checkpoint inhibitor activity of CD96 within blocking antibodies. Genentech recently published a paper in which they actually claimed that CD96 in the human is a cost-simulatory molecule. On the other end, indeed, the initial mouse studies did point for an inhibitory checkpoint activity of CD96 in the mouse. And GSK are pursuing, from what we understand from the press release, they are pursuing a blocker antibody. So the biology is maybe complex, and we need to see more data from GSK. Why do you think differently from Genentech, for example, who published a post-monitor role? And again, even if it is a negative checkpoint, we need to see its dominance, since it binds a bit weaker to PVR compared to PGT.
50:52 That's great. Thank you very much. The next question is from Rennie Benjamin of JMP Securities. Please go ahead.
51:08 Hi, this is Justin Walsh. I'm for Rennie. Given the mechanism of action of CON701, the combination approach, of course, makes a lot of sense to us. Could you provide some color on your reasoning behind choosing to test nivolumab over other PD-1 or PD-L1 inhibitors? And then to follow up with that, if you do see positive results with NEVO in either the doublet or the triplet, should we expect that you'd stick with NEVO as a combo partner longer term for COM701, or do you have plans to potentially explore other checkpoint inhibitors?
51:45 Yes, thank you. So the selection of Nevo over other drugs was not specifically because we think that Nevo is a very different PD-1 blocker compared to other PD-1 blockers. So we had our own business reasons, and that's the reason for selection. Obviously, as long as we have the collaboration with BMS, we will Work closely with them, continue to work closely with them and use NEVO. At the end of the day, we look at it as a proof of concept for the combination with PD-1 blockers. And it doesn't mean that in the future, COM-71 can't be combined with a completely different PD-1 blocker.
52:36 It's really serving us as a way to prove the hypothesis and obviously to do business with the BMS.
52:48 Perfect. Thank you very much. That's all for me. The next question is from Tony Butler of Ross Capital. Please go ahead.
53:02 Good morning. Thank you. I have three brief questions, if I may, and I'll just recite them all at once, if that's okay. Number one is that COM701, correct me if I'm wrong, but doses once every four weeks, and obviously NEVO and what you are attempting to do with 902 are every three weeks. Is there any thought as to perhaps creating a change that it may be easier certainly for the patient to come in and have dosing for all three, if you will, every three weeks as opposed to one which would be every four? That's question one. Obviously, Tregs in the tumor microenvironment are not necessarily beneficial.
53:54 In a TIDGET positive Treg in the tumor microenvironment, you also have upregulation of TIN3. And some companies have moved forward with anti-TIN3 antibodies. I'm just curious of your view of TIN3 in a dominant negative regulatory sense and how that may stick out as a potential impediment, if you will, even under the triple combination scenario. And then the final question is on PD-1 refractory patients. Do you know or can you hypothesize, is PD-RL2, does it change, does the expression change from, say, potentially a naive tumor that hasn't seen PD-1 to one that then has seen PD-1 has become refractory.
54:48 One might anticipate that PD-RL2 stays the same. Alternatively, that it diminishes in its expression. I'm just curious. I don't know that data. I'm sure you do. Thank you very much.
55:02 So, yes, thank you. I'll start with your last question about PDRL2. We are at the exploratory stage. We will collect data from biopsies, pre-treatment, on-treatment, patients that did got treatment with the PD-1 and were refractory or not, so we will have this information. As of now, we still do not have any such clinical information, so we can't really refer to this. I'll let Henry address the Q4 weekly question. Henry?
55:45 Yes, thank you, Ana. Tony, good question. So if you remember, we already disclosed data on the TK profile of COM701 at SIPC last year. And that data we disclosed on the PK showed that we can actually dose COM701 at Q3 weeks dosing also. And more recently, we disclosed data from Mass General Dr. Ryan Sullivan's presentation at AACR that we can also dose Q4 weekly. The dosing that we have selected for COM902 is based on what the preclinical data shows. During the course of the clinical trial that we are currently undergoing now, we will be able to better define what the PK profile of COM902 is based on the data that we collect from the patients on the study.
56:39 And then that will inform what the eventual dosing pattern that we're going to use will be at the recommended dose for expansion of the selected dose. So that's how we intend to do that. Now, if it's Q3 weeks or Q4 weeks, we're in a very good position because we can do either of those in combination with COM701.
56:59 Thank you. And then, yes, thank you, Ine.
57:06 Yes, please. Yeah, with respect to Team 3 and TIG, is there a letter on there related?
57:11 Well, Team 3 is obviously another player in the tool macro environment. It's actually the most dominant expression of team three is probably on maybe a more yellowish, so some people envisage it more as a yellowish target. But in general, one needs to look at the dominance of each of the pathways, team three and its ligands, how dominant they are. And until now, the clinical results, well, they are still evolving, but I'm not sure we've seen something very convincing to this point. And so as team three, there are also other players in tumor environments that maybe should be overcome in some tumor settings. But we are moving into education in which we think that our pathways are dominant, and this way, medical intervention in these tumor types will make clinical benefits.
57:58 Thank you for your time. This concludes our Q&A session. I will now turn the call back to Compugen's President and CEO. Dr. Cohen-Dayag, would you like to make your concluding statement?
58:21 Thank you. We're very pleased with the progress we're making across our clinical programs. We have met important milestones so far this year, and we anticipate providing multiple data readouts from our ongoing COM701 and COM902 Phase 1 studies in 2021, as I have detailed in my prepared comments. Our clinical development plan is designed to strategically evaluate the DENAM axis as a potentially transformative checkpoint axis for cancer immunotherapy treatment, and we're uniquely positioned to test this hypothesis and the potential contribution of PVRAD in expanding immunooncology treatment options beyond PD-1 blockers.
59:09 Our confidence in the validity of our hypothesis, which we first introduced when only PD-1 was clinically validated, has grown in recent months, given the preliminary anti-tumor activity of COM7-1 treatment we have shown and the clinical validation of PD by others. We look forward to continue updating you on our progress throughout the year. Thank you all for joining us today. Stay safe and healthy. Thank you. This concludes the Compugen Ltd. Second Quarter 2020 Financial Results Conference Call. Thank you for your participation. You may go ahead and disconnect.
Follow Compugen Ltd. into a list and get an email when it puts out news.
Director of Investor Relations and Corporate Communications
President and CEO
Chief Medical Officer
VP Research and Drug Discovery
CFO and COO
Analyst, Stiefel Financial
Analyst, SVB Leerink
Analyst, Oppenheimer & Co.
Analyst, SunTrust
Analyst, Jefferies
Analyst, JMP Securities
Analyst, Ross Capital